Endocrine Abstracts

Introduction: Somatostatin analogues (SSA) present the treatment of choice in patients with previously poorly controlled acromegaly.Methods: We conducted a retrospective analysis of acromegalic patients enrolled in the Network of Excellence for Neuroendocrine Tumors Munich and treated with the SSA lanreotide.Results: Fifty-six acromegalic patients (25 females; mean age 59 years; 33 with macroadenoma) switched to lanreotide from pre...